Abstract
Amyloid β-peptide (Aβ), which plays a central role in Alzheimer Disease, is generated by presenilin-dependent and presenilin-independent γ-secretase cleavages of β-amyloid precursor protein (βAPP). We report that the presenilins (PS1 and PS2) also regulate p53-associated cell death Thus, we established that PS deficiency, catalytically inactive PS mutants, γ-secretase inhibitors and βAPP or APLP2 depletion reduced the expression and activity of p53, and lowered the transactivation of its promoter and mRNA levels. p53 expression was also reduced in the brains or βAPP-deficient mice or in brains where both PS had been invalidated by double conditional knock out. AICDC59 and AICDC50, the γ- and η- secretase-derived C-terminal fragments of βAPP, respectively, trigger the activation of caspase-3, p53-dependent cell death, and increase p53 activity and mRNA. Finally, HEK293 cells expressing PS1 harboring familial AD (FAD) mutations or FAD-affected brains, all display enhanced p53 activity and p53 expression. Our studies demonstrate that AICDs control p53 at a transcriptional level, in vitro and in vivo and unravel a still unknown function for presenilins.
Keywords: Presenilins, nicastrin, caspase-3, p53 expression, transcriptional activation
Current Alzheimer Research
Title: The γ /η-Secretase-Derived APP Intracellular Domain Fragments Regulate p53
Volume: 4 Issue: 4
Author(s): Frederic Checler, Claire Sunyach, Raphaelle Pardossi-Piquard, Jean Sevalle, Bruno Vincent, Toshitaka Kawarai, Nadege Girardot, Peter St George-Hyslop and Cristine Alves da Costa
Affiliation:
Keywords: Presenilins, nicastrin, caspase-3, p53 expression, transcriptional activation
Abstract: Amyloid β-peptide (Aβ), which plays a central role in Alzheimer Disease, is generated by presenilin-dependent and presenilin-independent γ-secretase cleavages of β-amyloid precursor protein (βAPP). We report that the presenilins (PS1 and PS2) also regulate p53-associated cell death Thus, we established that PS deficiency, catalytically inactive PS mutants, γ-secretase inhibitors and βAPP or APLP2 depletion reduced the expression and activity of p53, and lowered the transactivation of its promoter and mRNA levels. p53 expression was also reduced in the brains or βAPP-deficient mice or in brains where both PS had been invalidated by double conditional knock out. AICDC59 and AICDC50, the γ- and η- secretase-derived C-terminal fragments of βAPP, respectively, trigger the activation of caspase-3, p53-dependent cell death, and increase p53 activity and mRNA. Finally, HEK293 cells expressing PS1 harboring familial AD (FAD) mutations or FAD-affected brains, all display enhanced p53 activity and p53 expression. Our studies demonstrate that AICDs control p53 at a transcriptional level, in vitro and in vivo and unravel a still unknown function for presenilins.
Export Options
About this article
Cite this article as:
Checler Frederic, Sunyach Claire, Pardossi-Piquard Raphaelle, Sevalle Jean, Vincent Bruno, Kawarai Toshitaka, Girardot Nadege, George-Hyslop Peter St and da Costa Alves Cristine, The γ /η-Secretase-Derived APP Intracellular Domain Fragments Regulate p53, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788945
DOI https://dx.doi.org/10.2174/156720507781788945 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-coding RNAs: Cracking the Code for Clinical Disease
Current Neurovascular Research Association of SORL1 Gene Variants with Hippocampal and Cerebral Atrophy and Alzheimer's Disease
Current Alzheimer Research Meet Our Editorial Board Member
Current Neuropharmacology Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-Propylpentanamide, a Valproic Acid Aryl Derivative with Activity Against HeLa Cells
Current Molecular Pharmacology Transcriptomics of Antipsychotic Drug Function: What have we Learned from Rodent Studies?
Current Psychopharmacology Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine Recent Advances in Drug Repurposing for Parkinson’s Disease
Current Medicinal Chemistry Meet Our Editorial Board Member:
Medicinal Chemistry Objective Biological Measures for the Assessment and Management of Auditory Processing Disorder
Current Pediatric Reviews Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Synthetic Applications of Enzymes Entrapped in Reverse Micelles & Organo-GelsΨ
Current Organic Chemistry A Sensitive HPLC-MS/MS Method for the Quantification of Selegiline in Beagle Dog Plasma: Application to a Pharmacokinetic Study
Current Pharmaceutical Analysis Development and Validation of 'Level A' In Vitro - In Vivo Correlation for Extended Release Tablets of Lamotrigine
Current Bioactive Compounds Pharmacological Applications of Lignins and Lignins Related Compounds: An Overview
Current Organic Chemistry Local Anesthetis and Adjuvants in Pediatric Regional Anesthesia
Current Drug Targets Patent Selections
Recent Patents on Drug Delivery & Formulation The Prevention of Adverse Drug Reactions in Older Subjects
Current Drug Metabolism Myeloperoxidase: The Good, the Bad, and the Ugly
Current Immunology Reviews (Discontinued) Brain MRI, Apoliprotein E Genotype, and Plasma Homocysteine in American Indian Alzheimer Disease Patients and Indian Controls
Current Alzheimer Research